On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on PRs and Gain Exclusive Benefits with NNW Prime! Click to View Details
ThursdayJul 06, 2017 12:47 pm

NetworkNewsBreaks – MassRoots, Inc. (MSRT) Shares Rise on Acquisition of Odava Compliance Platform

MassRoots (OTCQB: MSRT) shares are up 8% mid-day on news that the company has entered a definitive agreement to acquire Odava, Inc. for cash and shares of MassRoots’ common stock. Odava is a platform technology company that delivers compliance, point-of-sale, and supply chain management to streamline business operations for the cannabis industry. "We expect with MassRoots' resources and relationships, we can grow the number of dispensaries utilizing Odava from dozens to hundreds by early next year. In the near future, we believe a significant percentage of all transactions occurring in the regulated cannabis industry will occur on our platform," MassRoots…

Continue Reading

ThursdayJul 06, 2017 11:51 am

NetworkNewsBreaks – Catalyst Biosciences, Inc. (NASDAQ: CBIO) Reaches Financial Milestone in Subcutaneous Factor IX Program

Catalyst Biosciences (NASDAQ: CBIO) reports that it has achieved a financial milestone under its collaboration with ISU Abxis following the enrollment of the first patient in its hemophilia B clinical trial. In June 2017, the first patient and cohort were enrolled in a phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B to evaluate Catalyst’s next-generation Factor IX variant, CB 2679d/ISU304, for subcutaneous prophylaxis. ISU Abxis and Catalyst plan to have top-line data from the clinical trial by the end of 2017. “We are pleased to have achieved another financial milestone with the Factor IX clinical program, but…

Continue Reading

ThursdayJul 06, 2017 11:49 am

NetworkNewsBreaks – Cytori Therapeutics, Inc. (NASDAQ: CYTX) Shares Nudge Higher on New Key Cell Therapy Platform Patents

Cytori Therapeutics (NASDAQ: CYTX) this morning said it has received key patents that strengthen its intellectual property portfolio in the U.S. and Europe, sending shares up 2% mid-morning. To date, the company has 107 global patents issued in addition to 45 patent applications pending approval. Many of the most recently issued patents contain claims regarding the use of the company’s Habeo™ Cell Therapy for patients with scleroderma affecting the hands. "Our intellectual property strategy is to continue to strengthen the Cytori Cell Therapy™ platform to help establish and maintain a sustainable competitive advantage. Our main focus is on the primary…

Continue Reading

ThursdayJul 06, 2017 11:46 am

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Names Lead European Principal Investigator in Anticipated Annamycin Clinical Trial

Shares of Moleculin Biotech (NASDAQ: MBRX) are up 11% after the company named Dr. Lidia Gil of Poznan University of Medical Sciences in Poznan, Poland, as the lead European Principal Investigator for the upcoming planned phase I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML). The trial will commence if the company’s IND is permitted. "Dr. Gill is a dedicated investigator in AML and will bring significant expertise in the area as well as her potential to accelerate enrollment and the completion of our trial," Moleculin's chief medical officer, Dr. Robert Shepard, stated…

Continue Reading

ThursdayJul 06, 2017 10:21 am

NetworkNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Included in the Horizons Medical Marijuana Life Sciences ETF

ABcann Global Corporation (TSXV: ABCN) yesterday announced its inclusion in the Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ). The ETF is a first-of-its-kind index offering investors direct exposure to a basket of North American life sciences companies with significant business activities in the medical marijuana sector. “The Horizons ETF represents a new type of investment, a fund that tracks an industry in which there is considerable interest but which had no prior investment vehicle through which investors could gain broad exposure,” Aaron Keay, CEO of ABcann, stated in the news release. “Our inclusion in the ETF represents an important…

Continue Reading

WednesdayJul 05, 2017 1:21 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on July 5, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: DCIX 372.29% – News: Settles $148M secured loan facility with RBS with payment of $85M NWGI 35.80% – News: Obtains required certification for betting software platform CERU 32.09% – News: Issues letter to stockholders CLSN 23.27% – News: Completes OVATION study; provides update on immunotherapy trial BLFS 10.43% – News: Reaches agreement to modify existing credit facility SWEE 8.33% – News: Receives GRAS confirmation from independent panel regarding BESTEVIA™ Reb-D MTBC 7.63% – News:…

Continue Reading

WednesdayJul 05, 2017 12:10 pm

NetworkNewsBreaks – Soleno Therapeutics, Inc. (NASDAQ: SLNO) Surges on Positive Guidance from FDA for DCCR in Prader-Willi Syndrome

Soleno Therapeutics (NASDAQ: SLNO) shares are up 11% on news that the company has received the minutes from a scientific advice meeting from the U.S. Food and Drug Administration (FDA) regarding Diazoxide Choline Controlled-Release (DCCR) for the treatment of Prader-Willi syndrome (PWS). The company previously submitted data from a phase II study of DCCR in PWS patients, as well as data from other studies conducted with DCCR. The company agreed with the FDA’s suggestion that the duration of the study should be shorter and that DCCR safety information could be obtained in a long-term, safety extension study. Soleno said it…

Continue Reading

WednesdayJul 05, 2017 12:07 pm

NetworkNewsBreaks – DryShips, Inc. (NASDAQ: DRYS) Takes Delivery of Its Second Modern Newcastlemax Vessel; Shares Higher

Shares of DryShips (NASDAQ: DRYS) are up 12% mid-day after the company earlier said it has taken delivery of its previously announced 205,123 DWT Newcastlemax drybulk vessel. The vessel, which is the second for the owner of ocean-going cargo vessels, was built in 2013. Per a previous agreement, the vessel will be employed under a time charter contract with a major coal and steel trader for a gross rate linked to the new Baltic Capesize Index (BCI5TC) plus 20%. To view the full press release, visit: http://nnw.fm/1v0SD About DryShips Inc. The company is a diversified owner of ocean going cargo…

Continue Reading

WednesdayJul 05, 2017 11:45 am

NetworkNewsBreaks – Aegis Capital Issues ‘Buy’ Rating on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)

Aegis Capital has issued a ‘Buy’ rating on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE), citing the company’s recent filing of a Post-Grant Review (PGR) against Incyte Corporation’s (NASDAQ: INCY) U.S. Patent No. 9,662,335. The patent includes claims relating to Janus kinase inhibitors (JAKs), which affects Concert's deuterated ruxolitinib CTP-543, an oral JAK 1/2 inhibitor designed to treat alopecia areata. The analyst believes that the PGR process could resolve IP issues early, and the company appears confident in its case. For more information, visit www.concertpharma.com About Concert Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated…

Continue Reading

WednesdayJul 05, 2017 11:43 am

NetworkNewsBreaks – Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) Has “Buy” Rating Reiterated at Aegis Capital

Aegis Capital reiterated a ‘Buy’ rating and price target of $41 on shares of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) following the company’s recent report that eptinezumab met the primary and key secondary endpoints in PROMISE 1, a phase 3 pivotal clinical trial evaluating patients with frequent episodic migraine. The analyst noted that this positive news pushes the company one step closer to FDA approval for eptinezumab. Additionally, an upcoming catalyst for the company is the PROMISE 2 data expected in the first half of 2018. For more information, visit www.alderbio.com About Alder BioPharmaceuticals Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical…

Continue Reading

Contact us: 212.418.1217